| Document |
Document Title |
|
WO/2024/064769A8 |
The disclosure relates, in some aspects, to methods and compositions for production of immunogenic compositions. In some embodiments, the disclosure provides T cells which have been treated ex vivo with one or more oligonucleotide agents...
|
|
WO/2024/092105A2 |
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents or siRNAs, able to inhibit Complement Component C3 (C3) gene expression. Also disclosed are pharmaceutical compositions that include C3 RNAi agents and meth...
|
|
WO/2024/064787A3 |
Provided are ELISA based methods and compositions and kits for use in said methods, for quantitatively detecting the presence of double stranded RNA (dsRNA) in a sample solution, e.g., a sample solution that comprises dsRNA and messenger...
|
|
WO/2024/091058A1 |
The present invention relates to a cell panning method, a vector used in the method, and transformed cells used in the method. According to the cell panning method according to the present invention, an antibody having a binding ability ...
|
|
WO/2024/036331A3 |
Methods to create barcoded influenza viruses without disrupting the function of the viral proteins and the proper packaging of the viral genome segments are described. The barcoded influenza viruses can be used within deep mutational sca...
|
|
WO/2024/090883A1 |
The present invention relates to a pyruvate kinase 2 novel variant and a method for producing an L-aromatic amino acid using same. The pyruvate kinase 2 variant has protein activity that is altered by substitution of one or more amino ac...
|
|
WO/2024/064915A3 |
The invention provides methods for enriching nucleic acid target sequences from a sample, for example, from a biological sample or from a nucleic acid library. Further, wherein a nucleic acid enrichment method, comprises: cutting a nucle...
|
|
WO/2024/092120A2 |
siRNA molecules and pharmaceutical compositions containing siRNA molecules are provided for inhibiting expression of KRAS, RAF1 and mutant KRAS peptides or proteins. Methods of treatment of cancer are provided in which the pharmaceutical...
|
|
WO/2024/073374A3 |
Systems and methods, and associated compositions, for producing large libraries of nucleic acids are generally described. The methods provided herein may be used to produce libraries that include mutations that are unlikely in convention...
|
|
WO/2024/073375A3 |
Library screening is an important analytic tool for identifying functional nucleic acids or proteins. In some aspects, droplet-based systems and methods for library screening are provided. The systems and methods may include steps of sor...
|
|
WO/2024/055023A3 |
Compositions and methods are provided that enhance CAR T-cell therapy by providing an oncolytic virus engineered to direct expression and secretion of a multivalent adapter protein. The multivalent adapter protein targets both a broadly ...
|
|
WO/2024/006460A9 |
Biomarkers and machine learning techniques to identify biomarkers are disclosed herein. In one particular implementation, the present disclosure relates to the identification of biomarkers to be used in the detection and diagnosis of LD....
|
|
WO/2024/064752A3 |
Bio-adhesive derived from Vibrio cholerae (Vc) are provided. In some forms, the bio-adhesive includes a sequence of 57 amino acids within a major biofilm adhesin Bap1, and sequence variations thereof, that can be used as bioactive glue t...
|
|
WO/2024/090885A1 |
The present invention relates to a novel variant of the DNA-binding transcriptional regulator MalT and a method for producing an L-aromatic amino acid using same. The variant of the DNA-binding transcriptional regulator MalT has protein ...
|
|
WO/2024/089671A1 |
The present invention discloses a fusion protein SEQ ID NO: 1, comprising dodecin and Flavin Binding Fluorescent Protein (FBFP) for sequestering riboflavin to prevent the formation of skunk beer. The invention discloses the process of co...
|
|
WO/2024/087070A1 |
The present application relates to the technical field of biology, and specifically relates to a plasmid target, primer probe, kit and method for detecting residual host cell DNA in a cellular preparation or viral preparation. The plasmi...
|
|
WO/2024/087267A1 |
Provided is a chimeric antigen receptor capable of identifying and binding to TGFβRII. The chimeric antigen receptor is used in combination with a chimeric antigen receptor capable of identifying and binding to a tumor-specific antigen ...
|
|
WO/2024/089953A1 |
The present invention provides a method for producing oligonucleotide by a solid-phase synthesis technique, wherein said method for producing oligonucleotide comprises a step for reacting, in the presence of a thiol, an acid with an olig...
|
|
WO/2024/092171A1 |
The disclosure provides a method to assemble up to four viral, e.g., adeno- associated virus (AAV), genomes in vivo in a pre-designed configuration using a DNA recombination system to provide delivery of large genes that exceed the AAV' ...
|
|
WO/2024/092249A2 |
Provided herein is the identification of markers and genes associated with flower initiation in Cannabis. The markers are useful for breeding Cannabis plants that initiate flowering at longer daylightsdaylengths, which allows for earlier...
|
|
WO/2024/092248A1 |
Disclosed herein include light gated potassium selective channelrhodopsins (KCRs). Various embodiments include a KCR comprising an amino acid substitution that alters a property of the KCR. Certain embodiments are derived from a natural ...
|
|
WO/2024/091676A1 |
Embodiments of the instant disclosure relate to novel compositions and methods for generating thymic cells. In some embodiments, thymic cells can be differentiated from pluripotent stem cells (PSC), anterior primitive streak (APS) cells,...
|
|
WO/2024/044668A3 |
A method of isolating ultrashort single-stranded cell-free DNA (uscfDNA) is described as well as methods of using the uscfDNA for detecting biomarkers and diagnosing diseases and disorders.
|
|
WO/2024/054806A3 |
The present invention provides compositions and methods for inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella Typhi vector, wherein ...
|
|
WO/2024/091495A1 |
Among other things, the present disclosure provides compositions, e.g., recombinant adeno- associated virus (rAAV) vectors, comprising, e.g., an inhibitory nucleic acid (e.g., a miRNA) and/or a therapeutic nucleic acid sequence encoding ...
|
|
WO/2024/090491A1 |
The present invention provides a cell-membrane-permeable peptide for conjugation, represented by general formula (P1) [in general formula (P1): R101 is a 2-pyridyl group that may have a substituent; A1 is a cell-membrane-permeable peptid...
|
|
WO/2024/087423A1 |
An mRNA drug, which reduces expression in the liver after being delivered to the body, and a preparation method therefor. The preparation method comprises: establishing double 3'UTR in a target mRNA, and introducing a miR-122 binding sit...
|
|
WO/2024/087860A1 |
The present invention relates to a method for obtaining high-purity and high-stability recombinant human albumin by adding medium- and long-chain fatty acid ligands and removing a protein having charge heterogeneity by means of anion or/...
|
|
WO/2024/089293A1 |
The present invention discloses a method of therapeutically treating cancer, in particular CRC (colorectal cancer), or of reducing the risk of cancer in particular CRC, disease progression in a patient comprising expressing miR-326 in th...
|
|
WO/2024/090521A1 |
Provided is a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition containing a retinoic acid receptor (RAR) agonist.
|
|
WO/2024/091545A1 |
Nucleic acid error suppression is provided. In various embodiments, DNA is extracted from a collection of plasma samples. A sequence library with duplex adapters is prepared. The library is prepared by ligating a duplex adapter having a ...
|
|
WO/2024/086999A1 |
Provided is a method for regulating migrasome formation by a cell and/or migrasome-mediated biological process, comprising regulating the amount and/or function of PIP2 related pathway in said cell.
|
|
WO/2024/031008A3 |
siRNA molecules targeting AGT mRNA that reduce or inhibit AGT production are provided. Pharmaceutical compositions containing such siRNA molecules also are provided, together with methods of their use for treating hypertension. Pharmaceu...
|
|
WO/2024/059622A3 |
The present disclosure provides methods for co-amplifying RNA and DNA from a biological sample in a single reaction compartment. In some aspects, allowing for simultaneously generating RNA and DNA sequencing libraries. In particular, the...
|
|
WO/2024/091286A1 |
A composition for treating Huntington's disease (HD) by reducing endogenous Huntingtin (HTT) levels in a target includes an ASO comprising an ASO sequence selected from SEQ ID NOs:18 to 86, and a carrier peptide comprising a peptide sequ...
|
|
WO/2024/088190A1 |
Provided is an RNA inhibitor for inhibiting LPA gene expression or a pharmaceutically acceptable salt thereof. The RNA inhibitor is formed by base pairing of a sense strand and an antisense strand having a chain length of 15-30, and the ...
|
|
WO/2024/086929A1 |
Provided herein is a lipid nanoparticle comprising an encapsulated oligonucleotide molecule, wherein the oligonucleotide molecule is single-stranded or double-stranded and has a length of between 5 and 500 nucleotides; and 20 to 70 mol% ...
|
|
WO/2024/089124A1 |
The invention relates to a catechol O-methyltransferase (COMT) inhibitor for use in the treatment of osteoarthritis, the inhibitor being intended to slow down the progression of osteoarthritis and reduce osteoarthritis pain, as well as t...
|
|
WO/2024/091804A1 |
Certain embodiments of the disclosure are related to, inter alia, mutant and/or modified Bacillus cells (strains) comprising enhanced protein productivity phenotypes, mutant and/or modified cells comprising enhanced/increased ilvE messen...
|
|
WO/2024/090458A1 |
The purpose of the present invention is to provide: a substance which has an activity of binding to an inhibitory KIR to inhibit the cytotoxic activity of an NK cell and is useful for allogeneic technologies associated with organ transpl...
|
|
WO/2024/059733A3 |
Chimeric antigen receptors (CAR) with a binding domain that binds Nectin-4 are disclosed. The Nectin-4 binding domain can be derived from the murine antibody M22-321b41.1. The CAR disclosed herein can be expressed by an immune cell to be...
|
|
WO/2024/091949A1 |
The disclosure provides methods and systems for sample screening which may involve screening samples in presence and/or absence of effectors (e.g., encoded effector/compound libraries) for their potential effects on the sample or a targe...
|
|
WO/2024/087539A1 |
An enhanced StayGold yellow fluorescent protein and the use thereof, which relate to the technical field of recombinant proteins. With regard to the enhanced StayGold yellow fluorescent protein, the amino acid sequence of StayGold compri...
|
|
WO/2024/092164A1 |
Disclosed herein include novel blood-brain barrier (BBB)-crossing receptors on the BBB interface, targeting peptides and derivatives thereof capable of binding to the novel receptors, and related methods of using the receptors to increas...
|
|
WO/2023/214405A9 |
Methods of predicting clinical outcome in a subject suffering from cancer, detecting non-liver cancer in a subject, and methods of treating or preventing cancer or cancer-associated cachexia are provided. Synthetic lipid nanoparticles en...
|
|
WO/2024/088087A1 |
The present invention relates to the field of medical biology, and specifically to expression of a human papillomavirus (HPV) 68 L1 protein, and virus-like particles (VLPs) and a preparation method therefor. The amino acid sequence of th...
|
|
WO/2023/183528A3 |
The present disclosure provides compositions comprising IFNE and methods of using the same to treat cancer and/or enhancing responsiveness to immune checkpoint blockade therapy in a patient in need thereof. Also disclosed herein are comp...
|
|
WO/2024/092032A1 |
High-performance promoters, and other high-performance components, for the construction of CRISPR-based synthetic gene regulatory networks (GRNs) and methods for engineering and using the promoters and components. Activatable promoters w...
|
|
WO/2024/086925A1 |
Disclosed herein are cell-free protein synthesis systems, reaction mixtures for the same, and methods for preparing a protein of interest.
|
|
WO/2024/088384A1 |
Provided in the present invention are a gene editor for disease treatment and a nucleic acid pharmaceutical composition for an anti-fibrosis inhibitor. Specifically, the pharmaceutical composition contains: (a) a first active ingredient,...
|
